Equities researchers at Citigroup began coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $4.00 price target on the stock. Citigroup’s price target indicates a potential upside of 227.87% from the stock’s previous close.
A number of other brokerages have also commented on ABOS. HC Wainwright dropped their target price on Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, March 28th. UBS Group dropped their target price on Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, March 28th.
Get Our Latest Analysis on ABOS
Acumen Pharmaceuticals Price Performance
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. During the same period in the previous year, the business posted ($0.25) EPS. As a group, equities analysts forecast that Acumen Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Susquehanna Fundamental Investments LLC acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $25,000. Clune & Associates LTD. acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $28,000. Intech Investment Management LLC acquired a new position in shares of Acumen Pharmaceuticals during the 4th quarter worth approximately $32,000. Tower Research Capital LLC TRC raised its stake in shares of Acumen Pharmaceuticals by 427.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company’s stock worth $35,000 after buying an additional 16,714 shares during the period. Finally, AQR Capital Management LLC acquired a new position in shares of Acumen Pharmaceuticals during the 1st quarter worth approximately $46,000. 71.01% of the stock is owned by institutional investors and hedge funds.
Acumen Pharmaceuticals Company Profile
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.
Featured Articles
- Five stocks we like better than Acumen Pharmaceuticals
- How to buy stock: A step-by-step guide for beginners
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- Should You Invest in Penny Stocks?
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.